Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
11 October 2017
Question for written answer
to the Commission
Rule 130
Ramona Nicole Mănescu (PPE)

 Subject:  Relocation of the European Medicines Agency

The Commission has made a technical assessment of where to relocate the European Medicines Agency (EMA) and the European Banking Authority, in line with the procedure agreed by the EU-27. At the same time, independently of that process, the EMA conducted its own assessment, which it then published.

On what criteria were the studies conducted by the EMA based, and how does the Commission view those studies, which have repercussions for the image of certain Member States?

What steps does the Commission plan to take to compensate for the adverse effects of the EMA’s actions, given that these could have a negative impact on the assessment process and on the decision on where to relocate the European Medicines Agency?

Original language of question: RO 
Last updated: 9 November 2017Legal notice